Global Viral Vector and Plasmid DNA Manufacturing Market is expected to reach $1,090.3 million by 2023 from $321.3 million in 2017, registering a CAGR of 22.6% during the forecast period.

Increase in funding for R&D activities related to gene therapy due to prevalence of cancer and other genetic disorders coupled with rise in awareness regarding gene therapy drives the growth of the global viral vector and plasmid DNA manufacturing market. However, high cost of gene therapies and risk of mutagenesis and other impediments associated with gene therapy hamper the market growth. On the contrary, surge in demand for synthetic genes and untapped potential across emerging markets are expected to create lucrative opportunities for the market players in future.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/2681

The key market players analyzed in the report include Kaneka Eurogentec S.A., Brammer Bio, FUJIFILM Diosynth Biotechnologies, Spark Therapeutics, UniQure NV, MassBiologics, Kaneka Eurogentec S.A., Brammer Bio, Catapult, Biotechnologies, Sanofi, and Cobra Biologics.

The viral vector segment dominated the market in 2017, contributing more than two-fifths of the total market revenue, owing to advantages such as deep penetration in cells, site-specific integration, and ability to differentiate between non-dividing & dividing cells. Moreover, recent advancements in viral vectors to improve efficacy by using gene delivery have supplemented the market growth. However, the plasmid DNA segment is expected to register the fastest CAGR of 25.4% during the forecast period, owing to the increased demand for personalized medicines & target therapy and high success rate of prime boost immunization strategies in plasmid DNA vaccines. Furthermore, the non-viral vector is expected to witness steady growth during the forecast period.

The inherited disorder segment is expected to grow at the fastest CAGR of 25.1% during the study period, owing to the widespread applications of gene therapy and increase in usage of personalized medicine to treat chronic diseases. On the other hand, the cancer segment held the largest share in 2017, contributing nearly two-thirds of the total revenue, owing to the growing demand for high quality drugs and availability of versatile therapies for cancer treatment. The report also analyzes the viral infection and others segments.
North America accounted for more than two-fifths of the total market revenue in 2017, owing to the high prevalence of cancer, increase in adoption of experimental medicines, and rapid development of healthcare infrastructure. However, the Asia-Pacific region is expected to register the fastest CAGR of 29.5% through 2023, owing to rapid industrialization, increase in disposable income, and proactive government initiatives to improve healthcare infrastructure in the region. The other regions analyzed in the report include Europe and Latin America, Middle East and Africa (LAMEA).

For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/2681